Our Pipeline

Our unique IND engine has helped us identify novel pathways and targets in immuno-oncology and other areas.

Oncology-Focused Pipeline with Multiple Clinical Candidates

Cabiralizumab (FPA008)

CSF-1R antibody
Pancreatic cancer (Combination with Opdivo® and chemo)
Multiple tumor settings (Combination with Opdivo®)
Multiple tumor settings in ADVISE trial (Combination with Opdivo®)
Pigmented villondular synovitus (PVNS)

Bemarituzumab (FPA144)

FGFR2b antibody
FIGHT Phase 1/3 trial (with chemo) in gastric/GEJ cancer

FPA150

B7-H4 antibody
Multiple tumor settings

FPT155

CD80-Fc
Multiple tumor settings

BMS-986258

TIM-3 antibody
Phase 1/2 trial in multiple tumor settings
Multiple tumor settings
Multiple tumor settings